Novocure Stock Plunges After Phase 3 TRIDENT Study Fails to Meet Primary Goal
Novocure’s Phase 3 TRIDENT trial failed to show survival benefit from earlier TTFields initiation in newly diagnosed glioblastoma.
Novocure’s Phase 3 TRIDENT trial failed to show survival benefit from earlier TTFields initiation in newly diagnosed glioblastoma.
NovoCure’s (NVCR) Medicare billing privileges were briefly revoked due to a paperwork glitch but fully restored retroactively on Feb 24, 2026. Patients continued care with zero expected revenue impact.
Novocure's Optune Pax wearable device wins FDA approval for locally advanced pancreatic cancer with gemcitabine + nab-paclitaxel. Phase 3 trial shows improved survival and delayed pain progression.